Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1S1 | Q96B36 | 8/20 | 0.49 |
| ▸ | LIMK2 | P53671 | 6/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 5/20 | 0.39 |
| ▸ | AKT2 | P31751 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | PRKACG | P22612 | 1/20 | 0.38 |
| ▸ | PRKACB | P22694 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | PHGDH | O43175 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3491790 | 0.83 | AKT2 (0.56) | LIMK2LIMK1AKT2PRKACAPRKACG | |
| SCHEMBL3494465 | 0.77 | PHGDH (0.44) | PHGDHUSP30MAP3K12 | |
| SCHEMBL3493446 | 0.73 | SYK (0.54) | PHGDHUSP30 | |
| SCHEMBL13369024 | 0.72 | AKT1S1 (0.40) | AKT1S1LIMK2LIMK1AKT2ROCK2 | |
| SCHEMBL13369025 | 0.72 | LIMK2 (0.40) | AKT1S1LIMK2LIMK1AKT2ROCK2 | |
| SCHEMBL13369027 | 0.72 | AKT1S1 (0.43) | AKT1S1LIMK2LIMK1AKT1 | |
| SCHEMBL3491999 | 0.71 | AKT2 (0.60) | LIMK2LIMK1AKT2PRKACAPRKACG | |
| SCHEMBL10194432 | 0.71 | AKT1 (0.69) | AKT1S1AKT2ROCK2AKT1 | |
| SCHEMBL3493470 | 0.70 | AKT2 (0.49) | LIMK2LIMK1AKT2PRKACAPRKACG | |
| SCHEMBL13657173 | 0.67 | AKT2 (0.68) | AKT1S1AKT2ROCK2AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | GRK2, GNAO1, PTGER1 | AKT1S1 63/4885LIMK2 1477/4885LIMK1 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.